iqvia weight loss prescriptions semaglutide tirzepatide q3 2024 GLP-1 RA prescription trends: January 2018 – December The FDA has approved the

An interruption of just six months before resuming treatment still reduced the cardiovascular benefit, leading to a 4% to 8% increase in risk, compared to continuous use

Phase 3 clinical trial data found that Foundayo helped people lose 12.4% of their weight, on average, at its highest dose after 72 weeks similar to the Wegovy pill but less than injectable versions of Wegovy and Zepbound

This partnership with Noom will empower the people we serve to take charge of their health through healthier habits and weight management to mitigate chronic conditions, and were excited to see the benefits it brings to our members. For other individuals at risk for type 2 diabetes, they will receive Nooms Diabetes Prevention Program (DPP) the first CDC-recognized digital behavior change program tailored to support those who have early indicators of the disease

Severe red flag

The Future of Wellness is In Your Hands We are living through an incredible moment in the story of personal health

Our sister site, BenefitsPRO, looks at the tough balancing act for HR leaders